Production of pharmaceutical-grade plasmids at high concentration and high supercoiled percentage

Vaccine

Volumn 28, Issue 8, 2010, Pages 2046-2052

  Cai, Ying ^a   Rodriguez, Stephen ^b   Rameswaran, Ramu ^b   Draghia Akli, Ruxandra ^a   Juba Jr , Robert J ^b   Hebel, Henry ^b  

^a VGX Pharmaceuticals Inc   (United States)

^b VGXI Inc   (United States)

Author keywords

DNA vaccine; High concentration; Plasmid; Production; Supercoiled

Indexed keywords

CYCLIC GMP; DNA VACCINE; ENDOTOXIN; PLASMID DNA; VIRUS ANTIGEN; VIRUS RNA; WART VIRUS VACCINE;

ARTICLE; BATCH FERMENTATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; INFLUENZA VACCINATION; NONHUMAN; OSMOLALITY; PRIORITY JOURNAL; PURIFICATION; SCALE UP; SMALLPOX VIRUS; TRANSGENE;

DNA; FERMENTATION; INFLUENZA VACCINES; PAPILLOMAVIRUS VACCINES; PLASMIDS; QUALITY CONTROL; SMALLPOX VACCINE; VACCINES, DNA;

EID: 76949084636     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.057     Document Type: Article

References (15)

1. Voss C. Production of plasmid DNA for pharmaceutical use. Biotechnol Annu Rev 13 (2007) 201-222
2. Hirao L.A., Wu L., Khan A.S., Satishchandran A., Draghia-Akli R., and Weiner D.B. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26 (2008) 440-448
3. Shamlou P.A. Scaleable processes for the manufacture of therapeutic quantities of plasmid DNA. Biotechnol Appl Biochem 37 (2003) 207-218
4. Przybylowski M., Bartido S., Borquez-Ojeda O., Sadelain M., and Riviere I. Production of clinical-grade plasmid DNA for human phase I clinical trials and large animal clinical studies. Vaccine 25 (2007) 5013-5024
5. Quaak S.G., van den Berg J.H., Toebes M., Schumacher T.N., Haanen J.B., Beijnen J.H., et al. GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. Eur J Pharm Biopharm 70 (2008) 429-438
6. Hebel H., Attra H., Khan A., and Draghia-Akli R. Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. Vaccine 24 (2006) 4607-4614
7. Yan J., Harris K., Khan A.S., Draghia-Akli R., Sewell D.A., and Weiner D.B. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 26 (2008) 5210-5215
8. Laddy D.J., Yan J., Kutzler M., Kobasa D., Kobinger G.P., Khan A.S., et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3 (2008) e2517
9. Durfee T., Nelson R., Baldwin S., Plunkett III G., Burland V., Mau B., et al. The complete genome sequence of Escherichia coli DH10B: insights into the biology of a laboratory workhorse. J Bacteriol 190 (2008) 2597-2606
10. Teeters M.A., Conrardy S.E., Thomas B.L., Root T.W., and Lightfoot E.N. Adsorptive membrane chromatography for purification of plasmid DNA. J Chromatogr A 989 (2003) 165-173
11. Ow D.S., Yap M.G., and Oh S.K. Enhancement of plasmid DNA yields during fed-batch culture with a fruR knockout Escherichia coli strain. Biotechnol Appl Biochem 52 pt 1 (2009) 53-59
12. Carnes A.E., Hodgson C.P., and Williams J.A. Inducible Escherichia coli fermentation for increased plasmid DNA production. Biotechnol Appl Biochem 45 (2006) 155-166
13. Hooper J.W., Golden J.W., Ferro A.M., and King A.D. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25 (2007) 1814-1823
14. Cupillard L., Juillard V., Latour S., Colombet G., Cachet N., Richard S., et al. Impact of plasmid supercoiling on the efficacy of a rabies DNA vaccine to protect cats. Vaccine 23 (2005) 1910-1916
15. Pillai V.B., Hellerstein M., Yu T., Amara R.R., and Robinson H.L. Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines. Vaccine 26 (2008) 1136-1141